Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423183 | 0.81 | PDE2A (0.61) | PDE2ALMNASMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL4436075 | 0.75 | KMT2A (0.40) | LMNASMN1; SMN2ALDH1A1KDM4ETSHR | |
| SCHEMBL4433293 | 0.72 | LMNA (0.74) | LMNASMN1; SMN2NNMTCYP1A2ALDH1A1 | |
| SCHEMBL8835612 | 0.71 | PDE2A (0.52) | PDE2ALMNASMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL31539836 | 0.70 | POLB (0.34) | NNMTRECQLALDH1A1TSHR | |
| SCHEMBL7052100 | 0.70 | PDE2A (0.55) | PDE2ALMNASMN1; SMN2CYP1A2RECQL | |
| SCHEMBL29450819 | 0.70 | PDE2A (0.55) | PDE2ALMNASMN1; SMN2CYP1A2RECQL | |
| SCHEMBL12701526 | 0.69 | PDE2A (0.48) | PDE2ALMNASMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL25622911 | 0.68 | PDE2A (0.53) | PDE2ALMNASMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL11744262 | 0.67 | PDE2A (0.52) | PDE2ALMNASMN1; SMN2L3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262006-A1 | Selective endothelin type-a antagonists | CONCERT PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262006-A1 | Selective endothelin type-a antagonists | EDNRA, EDNRB, ECE1 | PDE2A 732/4885LMNA 1125/4885SMN1; SMN2 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.